These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 11248327)

  • 1. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
    Lee JH; Lee KH; Kim S; Seol M; Kim SH; Kim WK; Lee JS
    Leuk Res; 2001 Apr; 25(4):305-12. PubMed ID: 11248327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study.
    Choi SJ; Lee JH; Lee JH; Kim S; Lee YS; Seol M; Ryu SG; Lee JS; Kim WK; Jang S; Park CJ; Chi HS; Lee KH
    Bone Marrow Transplant; 2005 Jul; 36(2):163-9. PubMed ID: 15937507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
    Pawson R; Potter MN; Theocharous P; Lawler M; Garg M; Yin JA; Rezvani K; Craddock C; Rassam S; Prentice HG
    Br J Haematol; 2001 Dec; 115(3):622-9. PubMed ID: 11736947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation.
    Takami A; Okumura H; Yamazaki H; Kami M; Kim SW; Asakura H; Endo T; Nishio M; Minauchi K; Kumano K; Sugimori N; Mori S; Takemoto Y; Shimadoi S; Ozaki J; Takaue Y; Nakao S
    Int J Hematol; 2005 Dec; 82(5):449-55. PubMed ID: 16533751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation.
    Grigg A; Kannan K; Schwarer AP; Spencer A; Szer J
    Intern Med J; 2001; 31(1):15-22. PubMed ID: 11478351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule.
    Damon LE; Johnston LJ; Ries CA; Rugo HS; Case D; Ault K; Linker CA
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):468-74. PubMed ID: 15138711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
    Choi SJ; Lee JH; Lee JH; Kim S; Seol M; Lee YS; Lee JS; Kim WK; Chi HS; Lee KH
    Leukemia; 2004 Nov; 18(11):1789-97. PubMed ID: 15385924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
    Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
    Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
    Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
    Visani G; Lemoli RM; Isidori A; Piccaluga PP; Martinelli G; Malagola M; Gugliotta L; Bonini A; Bonifazi F; Motta MR; Rizzi S; Castellani S; Tura S
    Bone Marrow Transplant; 2001 Apr; 27(8):829-35. PubMed ID: 11477440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia.
    Bahng H; Lee JH; Ahn JH; Lee JH; Lee JS; Kim SH; Kim WK; Lee KH
    Leuk Res; 2001 Mar; 25(3):213-6. PubMed ID: 11226516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
    Soiffer RJ; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman RL; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
    Blood; 1997 Apr; 89(8):3039-47. PubMed ID: 9108425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
    Li QB; Li L; You Y; Chen ZC; Xia LH; Zou P
    Acta Pharmacol Sin; 2009 Oct; 30(10):1471-8. PubMed ID: 19767767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.